Skip to main content
SpringerLink
Log in

Personalised Medicine Implementation in Low- and Middle-Income Countries

  • Conference paper
  • First Online:
6th International Conference on Nanotechnologies and Biomedical Engineering (ICNBME 2023)

Part of the book series: IFMBE Proceedings ((IFMBE,volume 92))

  • 141 Accesses

Abstract

The potential of Personalised Medicine makes it attractive to health systems, and personalised approaches are being applied in practice in highly developed countries. However, the implementation of personalised medicine in low- and middle-income countries (LMICs) faces a number of barriers. In this group of countries, where resources allocated for health are limited, innovation is often not a priority. Methods: database search was used to identify publication that describes barriers and prerequisites for the implementation of personalised medicine in LMICs. Results. Insufficient regulation, lack of necessary infrastructure, high costs, lack of training of healthcare providers, low awareness of policy makers and population about benefits are barriers to the implementation of personalised medicine. Strengthening research in the field of personalised medicine, aligned with international standards, on a continuous basis, generating evidence on the long-term benefits of personalised medicine is a prerequisite for the implementation of personalised medicine in LMICs. The collaboration between researchers, information exchange and knowledge transfer between different actors of the health system is an essential element to overcome barriers to the implementation of personalised medicine. Ensuring access to personalised medicine services by identifying solutions to reduce health inequalities is a priority for implementing personalised approaches in health systems in LMICS. Conclusion. Prioritization of personalised medicine at the national level will ensure the strengthening of research, financing and the creation of infrastructure necessary for implementation. Consolidated efforts of all actors involved: health system actors, decision makers, citizens are needed to develop and implement personalised medicine in low- and middle-income countries.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Jaskulski, S., Nuszbaum, C., Michels, K.B.: Components, prospects, and challenges of personalized prevention. Front. Public Health 11, 1075076 (2023). https://doi.org/10.3389/fpubh.2023.1075076

    Article  Google Scholar 

  2. Tussié-Luna, M.T., Aguilar-Salinas, C.A.: Precision Medicine for Metabolic Disorders in Low - and Middle - Income Countries: Areas of Opportunity and Challenges for the Future. Rev. Invest. Clin. 73(5), 316–320 (2021). https://doi.org/10.24875/RIC.21000344

    Article  Google Scholar 

  3. Drake, T.M., Knight, S.R., Harrison, E.M., Søreide, K.: Global inequities in precision medicine and molecular cancer research. Front. Oncol. 8, 346 (2018). https://doi.org/10.3389/fonc.2018.00346

    Article  Google Scholar 

  4. Herold, K.C., et al.: An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes. N. Engl. J. Med. 381(7), 603–613 (2019). https://doi.org/10.1056/NEJMoa1902226

    Article  Google Scholar 

  5. Personalized Medicine Coalition Homepage. https://www.personalizedmedicinecoalition.org/Userfiles/PMCCorprate/file/Personalized_Medicine_at_FDA_The_Scope_Significance_of_Progress_in_2021.pdf

  6. WHO Technical Report Series No. 1031, 2021. The selection and use of essential in vitro diagnostics. https://apps.who.int/iris/handle/10665/311567

  7. Union for International Cancer Control. The role of in vitro diagnostics treatment of cancer. https://www.uicc.org/sites/main/files/atoms/files/UICC-IVD-Report-single-web-FA.pdf

  8. Guglielmo, A., Staropoli, N., Giancotti, M., Mauro, M.: Personalized medicine in colorectal cancer diagnosis and treatment: a systematic review of health economic evaluations. Cost Effectiveness and Resource Allocation 16(1), 1–14 (2018). https://doi.org/10.1186/s12962-018-0085-z

    Article  Google Scholar 

  9. Huai-liang, Wu., et al.: All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits. Br. J. Cancer 128(4), 638–646 (2023). https://doi.org/10.1038/s41416-022-02111-y

    Article  Google Scholar 

  10. Sun, Li., et al.: A cost-effectiveness analysis of multigene testing for all patients with breast cancer. JAMA Oncol. 5(12), 1718–1730 (2019). https://doi.org/10.1001/jamaoncol.2019.3323

    Article  Google Scholar 

  11. Stephan, G., Oliver, W.: A European screening programme for familial hypercholesterolaemia: a call to action. Eur. J. Prev. Cardiol. (2023). https://doi.org/10.1093/eurjpc/zwad018

  12. Bellcross, C., et al.: Evaluation of a breast/ovarian cancer genetics referral screening tool in a mammography population. Genetics in Medicine: Official Journal of the American College of Medical Genetics 11(11), 783–789 (2009). https://doi.org/10.1097/GIM.0b013e3181b9b04a

    Article  Google Scholar 

  13. CDC Homepage. https://www.cdc.gov/genomics/disease/breast_ovarian_cancer/testing.htm

  14. Breast screening. Public Health Agency, Ireland. https://www.publichealth.hscni.net/sites/default/files/2022-12/Job_11_Breast_Screening_Higher_Risk_12pp_11_22.pdf

  15. University of Florida Health. https://ufhealth.org/news/2021/genetic-testing-hereditary-breast-ovarian-cancer-risks-now-part-routine-care-uf-health

  16. Pujol, P., et al.: Clinical practice guidelines for BRCA1 and BRCA2 genetic testing. Eur. J. Cancer 146, 30–47 (2021). https://doi.org/10.1016/j.ejca.2020.12.023

    Article  Google Scholar 

  17. Gidding, S.S., Wiegman, A., Groselj, U., et al.: Paediatric familial hypercholesterolaemia screening in Europe: public policy background and recommendations. Eur. J. Prev. Cardiol. 29(18), 2301–2311 (2022). https://doi.org/10.1093/eurjpc/zwac200

    Article  Google Scholar 

  18. Jiang, J., Jiang, S., Ahumada-Canale, A., et al.: Breast cancer screening should embrace precision medicine: evidence by reviewing economic evaluations in China. Adv. Ther. 40, 1393–1417 (2023). https://doi.org/10.1007/s12325-023-02450-z

    Article  Google Scholar 

  19. Koldehoff, A., et al.: Cost-effectiveness of targeted genetic testing for breast and ovarian cancer: a systematic review. Value in Health: The Journal of the International Society for Pharmacoeconomics and Outcomes Research 24(2), 303–312 (2021). https://doi.org/10.1016/j.jval.2020.09.016

    Article  Google Scholar 

  20. Hassan, T.A., Sáenz, J.E., Ducinskiene, D., Cook, J.P., Imperato, J.S., Zou, K.H.: New strategies to improve patient adherence to medications for noncommunicable diseases during and after the COVID-19 era identified via a literature review. J. Multidisciplinary Healthcare 14, 2453–2465 (2021). https://doi.org/10.2147/JMDH.S313626

    Article  Google Scholar 

  21. https://www.who.int/docs/default-source/primary-health/declaration/gcphc-declaration.pdf

  22. Rehman, A., Awais, M., Baloch, N.U.: Precision medicine and low- to middle-income countries. JAMA Oncol. 2(3), 293–294 (2016). https://doi.org/10.1001/jamaoncol.2015.5511

    Article  Google Scholar 

  23. Arksey, H., O’Malley, L.: Scoping studies: towards a methodological framework. Int. J. Soc. Res. Methodol. 8(1), 19–32 (2005). https://doi.org/10.1080/1364557032000119616

    Article  Google Scholar 

  24. International Consortium for Personalised Medicine. The ICPerMed vision for 2030. 2019;28. ICPerMed Homepage. www.icpermed.eu/en/icpermed-members.php

  25. Adeniji, A.A., Dulal, S., Martin, M.G.: Personalized medicine in oncology in the developing world: barriers and concepts to improve status quo. World J. Oncol. 12(2–3), 50–60 (2021). https://doi.org/10.14740/wjon1345

    Article  Google Scholar 

  26. Mulder, N.: Development to enable precision medicine in Africa. Pers. Med. 14(6), 467–470 (2017). https://doi.org/10.2217/pme-2017-0055

    Article  Google Scholar 

  27. Zgheib, N.K., Patrinos, G.P., Akika, R., et al.: Precision medicine in low- and middle-income countries. Clin. Pharmacol. Ther. 107(1), 29–32 (2020). https://doi.org/10.1002/cpt.1649

    Article  Google Scholar 

  28. Cardona, A.F., et al.: Precision medicine and its implementation in patients with NTRK fusion genes: perspective from developing countries. Ther. Adv. Respir. Dis. 14, 175346662093855 (2020). https://doi.org/10.1177/1753466620938553

    Article  Google Scholar 

  29. Rathnasamy, N., Mullapally, S., Sirohi, B.: Precision oncology in low and middle income countries: a word of caution. Int. J. Cancer Care and Delivery 1(1) (2021).https://doi.org/10.53876/001c.29768

  30. Pavani, C., Plonski, G.A.: Personalized medicine in Brazil: a new paradigm, old problems. Innov. Manag. Rev. 18(4), 365–381 (2021). https://doi.org/10.1108/INMR-04-2019-0048

    Article  Google Scholar 

  31. Semiz, S., Aka, P.C.: Precision medicine in the era of CRISPR-Cas9: evidence from Bosnia and Herzegovina. Palgrave Communications 5(1), 1–8 (2019). https://doi.org/10.1057/s41599-019-0346-2

    Article  Google Scholar 

  32. Chong, H.Y., Allotey, P.A., Chaiyakunapruk, N.: Current landscape of personalized medicine adoption and implementation in Southeast Asia. BMC Med. Genomics 11(1), 1–15 (2018). https://doi.org/10.1186/s12920-018-0420-4

    Article  Google Scholar 

  33. Haque, M., Islam, T., Sartelli, M., Abdullah, A., Dhingra, S.: Prospects and challenges of precision medicine in lower- and middle-income countries: a brief overview. Bangladesh J. Med. Sci. 19(1), 32–47 (2019). https://doi.org/10.3329/bjms.v19i1.43871

    Article  Google Scholar 

  34. Tekola-Ayele, F., Rotimi, C.N.: Translational genomics in low- and middle-income countries: opportunities and challenges. Public Health Genomics 18(4), 242–247 (2015). https://doi.org/10.1159/000433518

    Article  Google Scholar 

  35. Solis, N., Zavaleta, E., Wernhoff, P., Dominguez-Barrera, C., Dominguez-Valentin, M.: Challenges to bringing personalized medicine to a low-resource setting in Peru. Int. J. Environ. Res. Public Health 18(4), 1470 (2021). https://doi.org/10.3390/ijerph18041470

    Article  Google Scholar 

  36. Shih, Y.-C.T., Pan, I.-W., Teich, N.: Global challenges in access to and implementation of precision oncology: the health care manager and health economist perspective. Am. Soc. Clin. Oncol. Annual Meeting 42, 429–437 (2022). https://doi.org/10.1200/EDBK_359650650

    Article  Google Scholar 

  37. Iriart, J.A.B.: Medicina de precisão/medicina personalizada: análise crítica dos movimentos de transformação da biomedicina no início do século XXI. Cadernos de Saude Publica 35(3), e00153118 (2019). https://doi.org/10.1590/0102-311X00153118

  38. Radich, J.P., et al.: Precision medicine in low- and middle-income countries. Ann. Rev. Pathol. 17(1), 387–402 (2022). https://doi.org/10.1146/annurev-pathol-042320-034052

    Article  Google Scholar 

  39. Patrinos, G.P., et al.: Roadmap for establishing large-scale genomic medicine initiatives in low- and middle-income countries. Am. J. Hum. Genet. 107(4), 589–595 (2020). https://doi.org/10.1016/j.ajhg.2020.08.005

    Article  Google Scholar 

Download references

Acknowledgments

Study conducted with the support of the Doctoral School of Medical Science and the National Agency for Research and Development, project 20.80009.8007.26.

Author information

Authors and Affiliations

  1. Nicolae Testemiţanu University of Medicine and Pharmacy, Chisinau, Republic of Moldova

    Ilenuta Gusila, Alexandra Topa, Natalia Zarbailov, Natalia Lungu & Ghenadie Curocichin

  2. Health Centre of Ciorescu, Ciorescu, Republic of Moldova

    Ilenuta Gusila

  3. Health Centre of Muncesti, Territorial Medical Association of Botanica, Chisinau, Republic of Moldova

    Alexandra Topa

  4. The Moldovan-Swiss Project “Reducing the Burden of Non-Communicable Diseases in the Republic of Moldova”, Chisinau, Republic of Moldova

    Natalia Zarbailov

  5. Centre of Family Doctors No. 3, Territorial Medical Association of Botanica, Chisinau, Republic of Moldova

    Natalia Lungu

Authors
  1. Ilenuta Gusila
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexandra Topa
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Natalia Zarbailov
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Natalia Lungu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ghenadie Curocichin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ilenuta Gusila .

Editor information

Editors and Affiliations

  1. Department of Microelectronics and Biomedical Engineering, Technical University of Moldova, Chisinau, Moldova

    Victor Sontea

  2. Academy of Sciences of Moldova, Chisinau, Moldova

    Ion Tiginyanu

  3. Department of Microelectronics and Biomedical Engineering, Technical University of Moldova, Chisinau, Moldova

    Serghei Railean

Ethics declarations

Conflict of Interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

Copyright information

© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this paper

Check for updates. Verify currency and authenticity via CrossMark

Cite this paper

Gusila, I., Topa, A., Zarbailov, N., Lungu, N., Curocichin, G. (2024). Personalised Medicine Implementation in Low- and Middle-Income Countries. In: Sontea, V., Tiginyanu, I., Railean, S. (eds) 6th International Conference on Nanotechnologies and Biomedical Engineering. ICNBME 2023. IFMBE Proceedings, vol 92. Springer, Cham. https://doi.org/10.1007/978-3-031-42782-4_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-42782-4_44

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-42781-7

  • Online ISBN: 978-3-031-42782-4

  • eBook Packages: EngineeringEngineering (R0)

Publish with us

Policies and ethics

Search

Navigation